Catalyst Pharmaceutical CPRX Net debt / EBITDA
Net debt / EBITDA at other companies
Other financials
Where this comes from
Calculated from Catalyst Pharmaceutical’s reported figures.
Based on the most recent quarter.
The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Catalyst Pharmaceutical's net debt / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Catalyst Pharmaceutical's net debt / EBITDA?
- Catalyst Pharmaceutical (CPRX) reported net debt / EBITDA of -2.5× in Q1 2026.
- How has Catalyst Pharmaceutical's net debt / EBITDA changed year-over-year?
- Catalyst Pharmaceutical's net debt / EBITDA decreased by 14.8% year-over-year, from -2.1× to -2.5×.
- What is the long-term trend for Catalyst Pharmaceutical's net debt / EBITDA?
- Over 5 years (2020 to 2025), Catalyst Pharmaceutical's net debt / EBITDA has grown at a -5.4% compound annual growth rate (CAGR), from -3.1× to -2.4×.
- What does net debt / EBITDA mean?
- Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.